Author | Paes, Rodrigo de Almeida | |
Author | Andrade, Iara Bastos de | |
Author | Ramos, Mariana Lucy Mesquita | |
Author | Rodrigues, Marcus Vinícius de Araújo | |
Author | Nascimento, Vinícius Alves do | |
Author | Bernardes-Engemann, Andréa Reis | |
Author | Frases, Susana | |
Access date | 2022-01-24T13:46:58Z | |
Available date | 2022-01-24T13:46:58Z | |
Document date | 2021 | |
Citation | PAES, Rodrigo de Almeida et al. Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 116, p. 1-10, 2021. | pt_BR |
ISSN | 0074-0276 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/50856 | |
Language | eng | pt_BR |
Publisher | Fiocruz/IOC | pt_BR |
Rights | open access | pt_BR |
Title | Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi | en_US |
Type | Article | pt_BR |
DOI | 10.1590/0074-02760210207 | |
Abstract | Background: Treatment of mycoses is often ineffective, usually prolonged, and has some side effects. These facts highlight the importance of discovering new molecules to treat fungal infections. Objectives: To search the Medicines for Malaria Venture COVID Box for drugs with antifungal activity. Methods: Fourteen human pathogenic fungi were tested against the 160 drugs of this collection at 1.0 µM concentration. We evaluated the ability of the drugs to impair fungal growth, their fungicidal nature, and morphological changes caused to cells. Findings: Thirty-four molecules (21.25%) presented antifungal activity. Seven are antifungal drugs and one is the agricultural fungicide cycloheximide. The other drugs with antifungal activity included antibiotics (n = 3), antimalarials (n = 4), antivirals (n = 2), antiparasitcs (n = 3), antitumor agents (n = 5), nervous system agents (n = 3), immunosuppressants (n = 3), antivomiting (n = 1), antiasthmatic (n = 1), and a genetic disorder agent (n = 1). Several of these drugs inhibited Histoplasma capsulatum and Paracoccidioides brasiliensis growth (15 and 20, respectively), while Fusarium solani was not affected by the drugs tested. Most drugs were fungistatic, but niclosamide presented fungicidal activity against the three dimorphic fungi tested. Cyclosporine affected morphology of Cryptococcus neoformans. Main Conclusions: These drugs represent new alternatives to the development of more accessible and effective therapies to treat human fungal infections. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Micologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Centro de Ciências da Saúde. Instituto de Biofísica Carlos Chagas Filho. Laboratório Intermediário de Biofísica de Fungos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Centro de Ciências da Saúde. Instituto de Biofísica Carlos Chagas Filho. Laboratório Intermediário de Biofísica de Fungos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Centro de Ciências da Saúde. Instituto de Biofísica Carlos Chagas Filho. Laboratório Intermediário de Biofísica de Fungos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Centro de Ciências da Saúde. Instituto de Biofísica Carlos Chagas Filho. Laboratório Intermediário de Biofísica de Fungos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Micologia. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Centro de Ciências da Saúde. Instituto de Biofísica Carlos Chagas Filho. Laboratório Intermediário de Biofísica de Fungos. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Antifungal activity | en_US |
Subject | COVID Box | en_US |
Subject | Drug repurposing | en_US |
Subject | Pathogenic fungi | en_US |
Subject | COVID-19 | |
DeCS | COVID-19 | pt_BR |
DeCS | Reposicionamento de Medicamentos | pt_BR |
e-ISSN | 1678-8060 | |